The International Spinal Research Trust (ISRT) has selected a sub-set of the key molecular and cellular events underlying spinal injury and nerve regeneration, to be the focus of their funding and other means of research support. These priority targets are (i) to understand and to minimise the damage caused by spinal injury and the resulting inflammatory and fibrotic events, in order to prevent the establishment of a post-acute situation that is ill-placed for regeneration; and (ii) to understand and then to manipulate the integrated environment for regrowth that is created by the interplay of soluble and matrix-or membrane-associated factors, both trophic and inhibitory. Investigation and, ultimately, exploitation of these targets requires the development of standardised and representative animal models and the application of quantitative methods for assessing functional re-innervation. The ISR T will also sponsor the networking of different disciplines and technologies to apply the most productive skills to spinal repair.
Introduction

Since the foundation of the International Spinal
Research Trust (ISRT) in 1980, progress in the neurosciences has been dramatic. Our understanding of the basic biology of the nervous system has increased to such an extent that we now have profound insights into the growth and maintenance of the nervous system and are able to influence these phenomena in a way that is relevant to treating the nervous system's responses to pathological insult and to injury. As this progress in our understanding continues to accelerate, there is thus the real prospect of effective therapies for a number of the most intractable health problems facing human society. Alzheimer's disease, stroke, Parkinson's disease and multiple sclerosis are just a handful of the conditions where realistic prospects now exist for disease modifying therapies. Furthermore, the underlying advance of neurobiology on a broad front also offers opportunities for the amelioration and repair of spinal cord injury-an area that generally attracts fewer resources from both public and private sectors. ISRT's mission is to fund research that will exploit this newly encouraging situation to achieve the successful treat ment of spinal cord injury. Recently, ISRT has
Correspondence: Peter J Banyard adopted a more focused prioritisation for its research awards and this article describes the purpose and content of its strategy.
Current status: justifying realistic expectations of new advances
To date, meaningful advances in treating spinal cord injury have been confined to interventions designed to limit the tissue damage immediately following the acute Injury.
A study of more than 150 subjects with severely traumatised spinal columns, who died at the roadside and therefore within moments of the injury, reveals that the spinal cord was apparently intact in many cases because the series of cellular events initiated by the injury was interrupted by death.
! If these patients had survived for even a few hours, the usual signs of necrosis would have become evident; and at some stage, 12 -24 h after injury, macrophages (microglia)
would have entered the lesion and become activated locally. However, the CNS has an atypical inflamma tory response to injury. 2
As a result of this and similar observations, various agents have been tested for their ability to interfere with the damaging series of cellular events that follow injury to the spinal cord. Clearly, corticosteroids can moderate the inflammatory response and, after laboratory trials, the first National Acute Spinal Cord Injury Study (NASCIS I) was initiated in the USA in 1979.3 In this study, high (1000 mgjday) and low doses (100 mgjday) of methylprednisolone were given to patients within 48 -72 h of injury and continued for 10 days. 330 patients took part in this first double-blind randomised multi-centre trial. No significant differences were found between the patients treated with high or low doses of the steroid and laboratory studies subsequently suggested that too little methylpredniso lone was given too late in NASCIS 1. Meanwhile, naloxone was reported to be beneficial in animal models of spinal cord injury; and NASCIS 2 was initiated in 1985 to compare very high doses of methylprednisolone (30 mgjkg bolus and maintained at 5.4 mgjkgjh for 23 h), naloxone (5.4 mgjkg bolus followed by 3.0 mgjkgjh for 23 h) and placebo.
A total of 487 patients were randomised within 12 h of spinal cord injury in this new study and patients treated within 8 h were compared with those treated between 8 and 12 h after injury. This was, once again, a multi-centre trial and care was taken to achieve uniform grading of muscle groups on the standard clinical scale of 0-5. Follow-up scores were obtained at 6 weeks, 6
months and a year after admission to hospital. 4
Patients treated more than 8 h after injury did not differ markedly from placebo controls and may even have had a worse outcome 1 year after injury. The NASCIS trials have achieved two major advances. Firstly, they demonstrated that pharmacolo gical interventions, even those based on very familiar cell biology and well-established drugs, can yield benefits in spinal cord injury: an important encourage ment. Secondly, they indicate that the neuropathology of spinal cord injury gives us a 'window of opportunity' in which to intervene at the hyper-acute stage before the nervous tissue is further damaged by a cellular reaction to the initial trauma. This window closes approximately 8 h after injury, strongly indicating the need for intervention to begin at the accident site.
Nevertheless, the success of the NASCIS trials should not encourage us to rely on direct clinical studies alone, however appropriate this may seem to the prompt and direct introduction of beneficial new approaches into routine SCI management. Owing to the size, cost, complexity and duration of these trials, we need to develop the optimum agent for neural protection in the laboratory rather than in the clinic. 8
Only in the laboratory setting will we be able to study agents in the many combinations that are worthy of exploration, in a sufficiently timely and cost-effective manner, using the highest resolution methods of analysis and without the restrictions inherent in choosing only from pharmacological agents already approved for human use.
Further progress in this area is likely to occur as a A coherent approach to further progress -towards the repair of chronic injury
However, even these advances will not alone be sufficient for SCI. While the developments described above are having a significant impact on the acute management of spinal cord injury, it is most unlikely that they will deliver complete protection from long term neurological damage, even if they are delivered sufficiently early. They will also offer nothing to the currently intractable problem of the sequelae of established SCI. ISRT's strategy therefore includes these early stages within an integrated approach to SCI that also addresses yet more challenging objectives. The multi-component nature of the pathology underlying spinal cord injury and the complexity of modern neurobiology encourages a broad and essen tially serendipitous (or, perhaps, opportunistic) attack on a wide range of research targets. Yet, ultimately, this may not be the most effective policy for a funding body such as ISR T:
• It under-exploits the major advances made in recent years in the relevant fields of molecular and cellular neurobiology, which make possible the sub-division of an overwhelmingly complex cascade of biological events into realistically resolvable sub-problems. These can be tackled essentially separately, as parts of a relentless advance towards a full reconstruction of the steps required to minimise spinal cord damage and maximise functional regeneration.
• It is susceptible to unpredictable changes in focus over time, determined predominantly by the fields within which spontaneous grant applications arrive at ISRT, and perhaps by research 'fashions' led by neurobiological foci divorced from spinal cord biology. This risks a lack of purposeful persistence in tackling key spinal cord problems, and may therefore directly retard progress.
• It is likely to lead to the dissipation of funds across too broad an area of science to allow ISR T to make any noticeable difference to the overall efforts of the international research community. This is not as irrelevant a consideration as it might at first sight appear, for a charity dependent on attracting private donations and responsible to its constituencies of SCI patients, volunteer fund-raisers and sponsors.
• By viewing the final goal as one unstructured whole, it makes it almost impossible for the management of ISRT to plan fund-raising that matches the task in hand: the budget required to deal with the full spectrum of relevant biology is both too large to be acquired by a single charitable institution and virtually impossible to estimate in a meaningful way at this point in our detailed understanding of the underlying possibilities. Figure 1 will eventually have to be solved.
This philosophy has led to the identification of the following broad areas as core targets for future ISRT fundcd research ( Moreover, projects extending or developing relevant new technologies for specific application to spinal cord systems are an appropriate way to focus advances made elsewhere towards the resolution of SCI, and will therefore be supported by ISRT.
Understanding and treatment of early stage trauma and inflammatory processes
Three issues merit focused attention in the early aftermath of SCI:
• preventing early-stage local neuronal and glial death (see also next Section)
• understanding the natural history and effects of the inflammatory response to injury in the CNS around 50% of injuries, with 'solid core mJury comprising the remaining 17%. As well as the relevance of the model being limited to only a minority of human cord injuries, the restricted biochemical assessments routinely undertaken (so dium and potassium content of the extracellular fluid) mean that the insights to be gained from the model, at least as currently used, into the underlying pathophysiology of SCI are very limited. This is, in essence, an empirical approach to screening currently available therapeutic entities in animals prior to early clinical studies (of NASCIS trials). There is, therefore, a real risk that approaches that might be clinically used in defined patient SUb-populations will be unsuccessful in this model, and therefore not pursued further.
We therefore intend to support the development of alternative animal model(s) both to investigate the pathophysiology events in the medium-term post traumatic period (focusing on the first 10 days), and subsequently therapeutic and prophylactic interven tions.
The development of this animal model may diverge from the development of a model suitable for evaluating therapies promoting the repair of chronic lesions, although there are obvious syner gies, and a common model, if feasible, would have obvious advantages in analytical power. A key related consideration in our strategy is that the production of multiple models, each used by one or only a few laboratories and each only rarely pre-define an acceptable number of models that, together, will adequately reflect human SCI, it is self evidently more efficient if models with a broad range of acceptability to the SCI community can be developed consensually, operated according to a standardised protocol and analysed in mutually informative ways -indeed, this is one of the key strengths of the USA initiative. For these reasons, we favour the establishment of networks of laboratories wi th pre-existing, interlocking skills to develop such new animal models, rather than wholly new ventures with their associated heavy start-up costs and delays in reaching peak efficiency.
The choice of species will also be important. It is again inappropriate to impose inflexible requirements for the choice of species, but those other than the rat should be considered -not least because the available range of monoclonal antibodies, in situ hybridisation reagents, transgenics, gene 'knock-outs' and other genomic tools, and the amenability to electrophysio logical investigation, etc will be prime determinants of the power with which new models can be interrogated at the molecular and cellular levels. By deliberately seeking to integrate existing knowledge from different technologies and disciplines, this strategy aims to accelerate our rate of progress and maximise our cost-effectiveness. The model should examine:
• oedema in the injured spinal cord ISRT will therefore support a programme to evaluate the changes following acute SCI in man. ISRT sees an important role exists for the Trust in fostering productive links between groups specialising in neurophysiology, clinical imaging, human post mortem studies and relevant animal models.
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Experimental exploitation of the new descriptive biology of SCI The information gained from the basic but powerful descriptive biology described above should underpin trials, in the animal models, of imaginative new pharmacological manipulations. We recognise that interventions with early 'tool' reagents frequently offer the most powerful ways of probing particular descriptive hypotheses l8 , l9 but we are alert to the reality that this degree of focus can often fail to generate a body of agreed, comprehensive and fundamental information on which others can build.
The research community needs to recognise both that early experimental probing of individual mechanistic components of SCI and repair is likely to fail -because of our still incomplete understanding of the full range of contributing events --and that such failures cannot be allowed to discourage further exploration of the same phenomena as we learn more. As ISRT strategy changes with time, the emphasis in this first part of our strategic focus is likely to shift from a predominantly descriptive focus to one that repeatedly tests and refines the resulting picture pharmacologically and through genetic manipulations.
This development might, for example, start to examIne:
• the use of alternative approaches to 'neuroprotec tion' to prevent cell death immediately post-trauma
• stabilisation of the axonal cytoskeleton to minimise early retraction, thereby reducing the distance over which regeneration must be promoted In this regard, an important clarification from the descriptive phase would be to quantify the degree of axonal retraction and cell death that occurs away from the site of the acute lesion 2o -22 , a matter on which there are currently divergent reports.
Repair of chronic injury
Beyond minimising the immediate damage and the subsequent medium-term deleterious changes evoked by inflammation and axonal disconnection and retraction, the key objective of SCI research is then the induction of functional re-innervation. To achieve this, several challenging objectives must be met: Over the past few years, ISRT's primary focus has been on the second of these objectives; the equivalent emphasis will now be given to the first. Looking more broadly, the historical emphasis of trophic factor biology has been on soluble, diffusible agents, while the emphasis of inhibitory factor research has been on substratum effects. There is ample reason to try to complete this picture by integrating soluble inhibitory factors and substratum-derived permissive or trophic influences. Moreover, the concept of a purely passive substratum is clearly inappropriate, and studies should incorporate 'solid phase' cell-cell and substratum-cell information flows, via membrane receptors coupled to active signalling mechanisms. The overall 'environ ment for growth' may be considered as shown schematically in Figure 3 . 
Deficii3ncies Intlibitory
inter-factor synergies and regulatory cascades, changing temporal patterns, etc. Figure 3 The environment for regeneration. The integration of soluble and 'solid-phase' (substratum, matrix-and membrane associated) stimulatory and inhibitory factors is illustrated schematically. Deficiencies in the intrinsic levels of trophic agents can as readily contribute to defective repair as the presence of overtly inhibitory molecules. The cross-talk between non-neuronal cells, as producers of these agents, and neurons, as both procedures and responders and the likely sophisticated balance between the levels of these molecules changing over time, all contribute to generating a highly complex environment. Only by addressing this complexity in an integrated way can the manipulations required to stimulate effective nerve regeneration and repair be created number of new molecules -the netrins, semaphorins and related factors -regulating axonal outgrowth and the direction in which such outgrowth will occur. 3 7 , 38 These advances begin to distinguish neurite outgrowth (distance) from orientation (direction), with the interactions between these newly discovered molecules and the neurotrophic factors 39 offering both increased complexity but also the increased specificity of neurobiological control that will be required if future therapeutic interventions are to avoid non-selective effects on the whole nervous systems.
For the immediate future, the primary focus will be on the development of strategies to provide trophic stimulation of initial axonal outgrowth and continued elongation. Three broad approaches are worthy of support.
Evaluation of the role of neuronal trophic factors
Over the next few years, advances in human and animal genomics are likely to result in the identification of many more neural growth and survival factors than we currently recognise. 4 o The rate of current progress is already beyond the scope of this review to summarise in any detail. Characterisation of the regulation of biosynthesis and patho-physiological relevance of these factors will be an enormous task, beyond the resources of ISRT alone. The obvious involvement of multiple (changing) neurotrophic factors in varying but rigor ously controlled proportions across the time frame of spinal cord damage and repair dramatically exacerbates this problem. Successful repair is likely to need both 'de differentiative' factors to allow neuronal outgrowth and 'differentiative' factors to restore full function. Our approach to this enormous and complex problem is for ISRT to encourage the study of growth factors in spinal cord-specific systems (specific nerve tracks or neuro transmitter-defined subsets) including, in relevant animal models, an examination of the role of non-neuronal cells in factor production as well as their responses to these neural local hormones. The recent identification of neuregulins as messages between neurons and their non-neuronal support cells 41 offers the prospect of a more rigorous understanding of this still only vaguely perceived cell-cell synergistic inter-relationship. The most feasible approach is likely to involve contributions from numerous independent laboratories seeking to apply their skills and technologies to the spinal cord. While 'merely' extending the catalogue of neurotrophic factors with explicit relevance to SCI has intrinsic merit while we have only limited under standing of this area, the critical need is to translate knowledge of this catalogue into practicable ap proaches to the manipulation of injury and repair.
Countering the effects of inhibitory factors
The concept of inhibitory factors in the central nervous system warrants significant further effort42,43 because it is likely to remain a major obstacle to successful repair The enhanced retrograde axonal transport of some NTFs that has been observed after axotomy l8 may bypass some of the conceptual drug delivery problems involved in promoting spinal core repair. Thus, the neuronal system may allow damaged neurons to be preferentially stimulated, avoiding potentially deleter ious effects from overgrowth of undamaged and functional neurons, and may also allow motor neurons to be modulated without intercranial admin istration of drugs.
With these perspectives in mind, it is clear that the issues surrounding the administration of putative SCI treatments will eventually become rate-limiting. ISRT regards a heavy emphasis on this area as premature at present, but recognises that turning to these issues only after solution of the intrinsic regeneration problem is also inappropriate. Research into model systems and approaches that are cognisant of the ultimate practical requirements for SCI treatment will therefore be favoured.
Functional assessment
As spinal cord biology, and neurobiology in general, has made promising advances, we feel that the time has come to impose on ourselves a more challenging criterion for success. Morphological evidence of the regeneration of a few, hesitantly-growing axons is encouraging as a first step, but falls well short of the needs of the SCI patient. In particular, such a restricted result can lead to the premature interpretation of work on growth-inhibitory molecules as indicating successful regeneration when all that might have been achieved are very local perturba tions in an essentially still growth-blocked environment. Furthermore, anatomical changes are poorly representa tive of functional consequences: it is noteworthy that rats may show full functional recovery following experimental SCI in the presence of histologically demonstratable persistent destruction of the lateral cortico-spinal tracts. Moreover, any correlation of anatomical changes with function in animals may very well not be directly applicable to man.
In addition, regrowth that can be anatomically demonstrated may actually be functionally incompe tent or even deleterious. Local, high resolution 'Darwinian' exploration of the effector cells may be required to produce an appropriate innervation pattern. Inappropriate innervation patterns at effector cell level may be compensated for by re-organisation of th � . central conne � tions (impl�in� very sophisti . cated plastICity and adapbve controls 5-). These are Issues that extend beyond ISR T's current strategy, although they will have to be addressed in the future. The ultimate objective for spinal cord repair is the restoration of functional innervation. Therefore, ISRT will favour studies that:
• apply existing technologies, particularly neurophy siology, to determine the nature of loss of function in SCI, and the reaction of the intact nervous system to damage, and to track regenerating SC systems improvements in the development of new treat ment strategies to be assessed nor their ultimate tailoring to individual patient needs during treat ment, as may be necessary given the inevitable differences in pathology between SCI cases An a priori requirement for evaluating strategies for the repair of chronic SCI will be the existence of a validated, functional animal model. There is currently no generally accepted animal model of chronic spinal cord injury. In any event, as noted above, there appear to be at least three distinct patterns of anatomical change following chronic injury in hu mans. As dis-cussed above, integrating animal models of acute and chronic SCI would have self-evident benefits, but it is recognised that this may be an almost impossible task.
There is considerable scope for using neurophysiol ogy to measure damage and to detail functionally competent regeneration. Existing detailed understand ing of cat neurophysiology and behaviour may usefully be exploited. The necessary neurophysiological skills can readily be accessed in most research institutions through appropriate collaborations: a consistent thread through ISR T's strategy is the concerted application of pre-existing skills to SC problems, to capture their maximum potential. Standardised neuro physiological measures are important to define the extent of lesions and the extent of recovery in models used in different laboratories world-wide. Following the development and validation of such a functional model, ISRT will require that physiological evidence be provided for restoration of function in research projects funded by the Trust .
Risks and opportunities
As already discussed, it is well recognised that the delineation of a focused research strategy carries both the risk that the selection is wrong and the danger that, inflexibly applied, it will exclude new developments, innovative thinking and the entry into the field of scientists experienced in other fields who could make a substantial impact on the field of spinal cord injury by the application of different thinking. ISRT self evidently wishes to avoid these pitfalls.
It is therefore axiomatic that the strategy outlined here will remain valid only for a strictly limited time. It is the intention of ISRT regularly to evaluate and update the proposals at appropriate intervals and to disseminate the resulting documentation to all inter ested parties. In particular, we intend to establish close relationships with the other voluntary grant-giving bodies with a particular interest in the area of spinal cord injury.
Without wishing to blur the edges of our strategy by denying the intention to focus the majority of our research funds on the areas described in this review and the attendant consequence that other areas will receive reduced support, ISR T will remain open to the innovative, even iconoclastic, proposal that promises to break radically new ground, and which merits a short-term 'pump-priming' award.
Underpinning the whole concept of creating an integrated approach to treating SCI is the need to encourage cross-disciplinary awareness and co-opera tion. ISR T will, therefore, support:
• temporary secondments of scientists and clinicians between institutions to strengthen, in a directly practical way, the networks required to achieve the integrated research goals described in this review 
